COMPANIES TO WATCH

• Companies To Watch: Terns Pharmaceuticals

  Terns Pharmaceuticals aims to improve upon currently marketed therapies in CML and obesity, using internally discovered small molecules.

• Companies To Watch: Spinogenix

  Spinogenix is using small molecule drugs to regenerate synapses in patients with ALS, Alzheimer's disease, schizophrenia, glaucoma, and Fragile X syndrome.

• Companies To Watch: Aurion Biotech

  Aurion Biotech is developing what could become the first allogeneic combination cell therapy for the treatment of corneal endothelial diseases.

• Companies To Watch: Athira Pharma

  Athira Pharma is developing small molecule therapeutics for neurodegenerative diseases, including its lead candidate, fosgonimeton, for Alzheimer's disease.

WHERE ARE THEY NOW

• Where Are They Now? Teva Pharmaceuticals

  Teva Pharmaceuticals "pivot to growth" strategy under CEO Richard Francis aims to use a combination of biosimilars, generics, and branded drugs to set the company back on track, or back to the future.

• Where Are They Now? Ironwood Pharmaceuticals

  Ironwood Pharmaceuticals is a smaller company than it was in 2016, when Life Science Leader wrote a feature article about its founder and mission. But Peter Hecht, Ironwood's former CEO, who now leads Tisento Therapeutics, has practiced what he preached.

• Where Are They Now? Carisma Therapeutics

  In three years, Carisma Therapeutics has gone public, entered a broad collaboration with Moderna, and ceased development of its original CAR-Macrophage candidate, in favor of CAR-Monocyte therapies. Carisma expects to release CT-0525 Phase 1 data by the end of 2024.